Since its original description by Haïssaguerre et al., catheter ablation of atrial fibrillation (AF) by electrically isolating the pulmonary veins has evolved over the past 15 years and is now a commonly performed procedure in many major centers throughout the world.[@b1],[@b2] Small, randomized, clinical trials have demonstrated that catheter ablation results in increased freedom from AF, when compared with medical therapy.[@b3] In general, the patients included in these trials have been relatively young (mid to late fifties) with drug-refractory paroxysmal AF and minimal comorbidity.[@b3],[@b4] Hence, there may be considerable bias in the absolute event rates reported. Consistent with this evidence base, the only class I indication for ablation of AF in the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society Guideline for the Management of Patients With Atrial Fibrillation is symptomatic paroxysmal AF in patients who are refractory or intolerant to at least 1 class I or III antiarrhythmic medication.[@b2]

Although differences in characteristics between patients with rhythm-or rate-controlling strategies have been described, with the patients on rhythm control being younger and with less comorbidity,[@b5],[@b6] the characteristics of the subset of patients undergoing AF ablation in community practice, as opposed to randomized trial populations, is not well described. Some registry data indicate that patients referred for AF ablation in community practice may be substantially older than those in the randomized, clinical trials,[@b1],[@b7] but further details on patient and/or arrhythmia characteristics are lacking. The objective of the present study was to describe the utilization of catheter ablation in a contemporary U.S. clinical practice and describe the characteristics and subsequent outcomes in these patients.

Methods
=======

The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) study is a contemporary registry of outpatients in the United States with AF managed by a variety of providers, including internists, cardiologists, and electrophysiologists. Its design has been described in detail elsewhere.[@b8] In brief, a nationally representative sample of sites was invited to participate and an adaptive design was used to ensure provider and geographical heterogeneity, although enrollment was not formally stratified. Consecutive patients with AF, meeting all the inclusion criteria (at least 18 years of age, electrocardiographic \[ECG\] evidence of AF, providing informed consent) and none of the exclusion criteria (life expectancy of less than 6 months or AF secondary to reversible conditions) were enrolled. For the purpose of this analysis, patients with a history of surgical or hybrid maze or missing data for previous AF catheter ablation were excluded.

Data collection included demographics, past medical history, type of AF and previous interventions, ongoing antithrombotic therapy (with monitoring), vital signs, laboratory studies, ECG findings, and echocardiographic findings. Previous and incident electrophysiology interventions are also captured, including both catheter-based and surgical ablations for AF and atrial flutter. In ORBIT-AF, follow-up data collection occurs at 6-month intervals for a minimum of 2 years. For the current study, all available follow-up for the outcomes was used for analyses.

Statistical Analyses
--------------------

The entire baseline ORBIT-AF population included 10 132 patients enrolled between June 29, 2010 and August 9, 2011 from 176 sites. The current analysis excluded 197 patients: 194 resulting from surgical or hybrid maze and 3 from missing data for AF catheter ablation at baseline. This yielded a final study population of 9935 patients from 176 sites.

Data are presented as frequencies and percentages for categorical variables and medians (interquartile range) for continuous variables. Groups are compared using the chi-square test for categorical variables and the Wilcoxon rank-sum test for continuous variables.

To identify factors associated with the binary outcome "previous catheter ablation," a multivariable hierarchical logistic regression model was used, with site included as a random effect to account for site variability in ablation. Variable selection was conducted by backward selection with a significance level of 0.05. The list of candidate variables is provided in [Data S1](#sd1){ref-type="supplementary-material"}. Additionally, Cox frailty models (which account for clustered patients within a site) were used to examine the association of previous catheter ablation at baseline and time from enrollment to outcomes in follow-up (all-cause death, cardiovascular \[CV\] hospitalization or death, CV death, CV hospitalization, the composite of death, stroke, transient ischemic attack \[TIA\] or new-onset congestive heart failure \[CHF\], and major bleeding) among 9451 patients (484 patients were excluded because of no follow-up data). Each outcome model was adjusted for all independent predictors previously identified from a prespecified list of candidate variables using backward selection and a significance level of 0.05. Last, to examine the association between previous catheter ablation at baseline and repeat hospitalizations (all cause, CV, bleeding and non-CV, and nonbleeding), negative binomial regression models were used. Variables from the all-cause hospitalization adjustment model were used for adjustment.

In the preceding regression models, continuous variables were evaluated for nonlinearity with the outcome and nonlinear relationships were addressed by using linear splines. Missing data were multiply imputed and final estimates and SEs reflect the combined analysis over 5 imputed data sets. Variable selection was conducted on the first imputed data set. Rates of missingness were less than 2% for all candidate variables in the models, with the following exceptions: level of education (4%); serum creatinine (8%); hematocrit (11%); estimated glomerular filtration rate (8%); left ventricular ejection fraction (LVEF; 11%); and left atrial diameter (16%). Results were presented as odds/hazard/rate ratios (OR/HR/RR) with corresponding 95% confidence intervals (CIs) and *P* values.

To examine the association between incident catheter ablation and subsequent outcomes, we employed propensity score matching to construct a matched cohort between patients with catheter ablation after enrollment in the registry (incident catheter ablation) and overall (non-catheter-ablated) patients having a similar disease course. A propensity score for having catheter ablation during follow-up versus no catheter ablation was created by logistic regression. Risk factors included in this model are reported in [Data S1](#sd1){ref-type="supplementary-material"}. Missing data of the risk factors were imputed to the mode. Catheter-ablated patients were matched to non-catheter-ablated patients using a 2 to 1 match matching exactly on duration of AF, AF type, and ever on rhythm control treatment strategy and matching on the linear predictor (X\*beta) from the propensity score model using a caliper for matching of 0.20\*std(X\*beta) using a greedy algorithm. Ultimately, 266 catheter-ablated patients were matched to 515 non-catheter-ablated patients. The outcome models were fit using the stratified Cox regression model with each case/control group forming a strata. Results were presented as HRs with corresponding 95% CIs and *P* values.

All statistical analyses of the aggregate, deidentified data were performed by the Duke Clinical Research Institute using SAS software (version 9.3; SAS Institute Inc., Cary, NC). All *P* values were 2 sided. The ORBIT-AF Registry is approved by the Duke Institutional Review Board, and all participating sites obtained institutional review board approval pursuant to local requirements. All subjects provided written, informed consent.

Results
=======

Baseline Characteristics
------------------------

Overall, 527 patients (5.3%) had a previous catheter ablation of AF at baseline. Median time between catheter ablation and inclusion in the study was 18 (5 to 51) months. [Table 1](#tbl1){ref-type="table"} shows the complete set of baseline characteristics in the overall study population and by previous catheter ablation of AF. Compared to nonablated patients, patients with a previous catheter ablation were younger (67 \[59 to 74\] vs. 75 \[67 to 82\] years; *P*\<0.0001), more often male, of white race, had a higher level of education, and were more often privately insured. They had a lower prevalence of hypertension, hyperlipidemia, anemia, diabetes, chronic obstructive pulmonary disease, and dementia. Moreover, patients with previous catheter ablation of AF were less likely to have suffered from a stroke or previous myocardial infarction. The notable exception was obstructive sleep apnea, which was more common in patients with previous catheter ablation of AF (26% vs. 18%; *P*\<0.0001).

###### 

Baseline Characteristics by Previous AF Ablation

                                                          Overall (N=9935)   No Previous AF Ablation (N=9408)   Previous AF Ablation (N=527)   *P* Value
  ------------------------------------------------------- ------------------ ---------------------------------- ------------------------------ -----------
  Age, y                                                  75 (67 to 82)      75 (67 to 82)                      67 (59 to 74)                  \<0.0001
  Female                                                  42                 43                                 38                             \<0.0001
  Race                                                                                                                                         
   White                                                  89                 89                                 94                             0.0008
   Black or African-American                              5.1                5.2                                3.0                            
   Hispanic                                               4.3                4.4                                1.5                            
   Other                                                  1.4                1.4                                1.0                            
  Level of education                                                                                                                           
   Some school                                            14                 15                                 6.1                            \<0.0001
   High school graduate                                   51                 51                                 50                             
   College graduate                                       23                 22                                 26                             
   Postgraduate                                           8.1                7.8                                14                             
  Geographical region                                                                                                                          
   Midwest                                                25                 25                                 30                             0.0002
   Northeast                                              26                 26                                 27                             
   South                                                  35                 35                                 35                             
   West                                                   14                 15                                 8.2                            
  Private insurance                                       26                 24                                 45                             \<0.0001
  Medical history                                                                                                                              
   Smoking                                                48                 48                                 48                             0.8
   Hypertension                                           83                 84                                 74                             \<0.0001
   Hyperlipidemia                                         72                 72                                 67                             0.0060
   Anemia                                                 18                 18                                 13                             0.0029
   Diabetes                                               29                 30                                 25                             0.0265
   Chronic obstructive pulmonary disease                  16                 16                                 13                             0.0410
   Obstructive sleep apnea                                18                 18                                 26                             \<0.0001
   Previous myocardial infarction                         16                 16                                 11                             0.0026
   Heart failure                                          32                 33                                 28                             0.054
   Implanted device                                       27                 27                                 30                             0.20
   Moderate/severe mitral stenosis                        1.3                1.3                                0.6                            0.14
   Previous cerebrovascular events                        16                 16                                 13                             0.0376
    Stroke (all-cause)                                    8.7                8.9                                5.5                            0.0069
     Nonhemorrhagic                                       7.9                8.0                                5.1                            0.0165
     Hemorrhagic                                          0.7                0.8                                0.2                            0.13
   Other intracranial bleeding                            0.9                0.9                                1.0                            0.9
   Gastrointestinal bleeding                              9.0                9.2                                6.1                            0.0150
   Cognitive impairment or dementia                       3.1                3.2                                0.6                            0.0006
   Frailty                                                5.8                5.9                                2.9                            0.0031
  BMI, kg/m^2^                                            29 (25 to 34)      29 (25 to 34)                      31 (27 to 35)                  \<0.0001
  Heart rate, bpm                                         70 (63 to 80)      70 (63 to 80)                      71 (63 to 80)                  0.9418
  Systolic blood pressure, mm Hg                          126 (116 to 138)   126 (116 to 138)                   124 (115 to 134)               0.0121
  Diastolic blood pressure, mm Hg                         72 (66 to 80)      72 (66 to 80)                      73 (68 to 80)                  0.0213
  Calculated creatinine clearance, mL/min per 1.73 m^2^   69 (50 to 97)      69 (49 to 95)                      92 (65 to 122)                 \<0.0001
  Left ventricular ejection fraction \>50%                70                 70                                 76                             0.0230
  Left atrial diameter, cm                                4.4 (3.9 to 5.0)   4.4 (3.9 to 5.0)                   4.4 (3.9 to 4.9)               0.3

Continuous variables are presented as median and interquartile range. AF indicates atrial fibrillation; BMI, body mass index; bpm, beats per minute.

AF Characteristics at Baseline
------------------------------

Baseline AF characteristics are summarized in [Table 2](#tbl2){ref-type="table"}. Patients with previous catheter ablation more often had a family history of AF, had longer history of AF, and were more likely to have paroxysmal AF (63% vs. 50%; *P*\<0.0001). Patients with previous ablation more frequently exhibited sinus rhythm on their baseline ECG (52% vs. 32%; *P*\<0.0001). They were more likely to have undergone cardioversion, and the vast majority had been treated with antiarrhythmic drugs (82% vs. 43%; *P*\<0.0001). They were also more symptomatic (31% vs. 16% with severe or disabling symptoms; *P*\<0.0001) and were more often on a rhythm-controlling strategy at baseline (57% vs. 30%; *P*\<0.0001). Their CHADS~2~ score was lower compared to patients without previous catheter ablation of AF (mean±SD; 1.8±1.3 vs. 2.3±1.3; *P*\<0.0001). Patients with previous AF ablation were more often treated by an electrophysiologist at baseline than those without previous ablation (42% vs. 15%; *P*\<0.0001).

###### 

AF History by Previous AF Ablation

                                     Overall (N=9935)   No Previous AF Ablation (N=9408)   Previous AF Ablation (N=527)   *P* Value
  ---------------------------------- ------------------ ---------------------------------- ------------------------------ -----------
  AF type                                                                                                                 
   First detected/new onset          4.8                5.1                                0.4                            \<0.0001
   Paroxysmal                        50                 50                                 63                             
   Persistent                        17                 16                                 22                             
   Long-standing persistent          28                 29                                 14                             
  Family history of AF               15                 14                                 24                             \<0.0001
  Duration of AF diagnosis, months   47 (18 to 93)      45 (17 to 91)                      69 (34 to 117)                 \<0.0001
  Sinus rhythm on most recent ECG    33                 32                                 52                             \<0.0001
  EHRA symptom level                                                                                                      
   No symptoms                       38                 39                                 26                             \<0.0001
   Mild                              45                 45                                 43                             
   Severe                            15                 14                                 26                             
   Disabling                         1.8                1.6                                4.6                            
  CHADS~2~ risk groups                                                                                                    
   0                                 6.4                5.8                                17                             \<0.0001
   1                                 22                 21                                 28                             
   ≥2                                72                 73                                 55                             
  Previous treatment                                                                                                      
   Oral anticoagulation therapy      82                 81                                 92                             \<0.0001
   Antiarrhythmic drug               45                 43                                 82                             \<0.0001
   Previous cardioversions           29                 28                                 55                             \<0.0001
  Current treatment                                                                                                       
   Oral anticoagulation therapy      76                 76                                 75                             0.5
   Antiarrhythmic drug               29                 28                                 46                             \<0.0001
   Rhythm strategy                   31                 30                                 57                             \<0.0001
  Treatment provider specialty                                                                                            
   Cardiology                        80                 81                                 73                             \<0.0001
   Electrophysiology                 17                 15                                 42                             \<0.0001
   Internal medicine/primary care    67                 68                                 59                             \<0.0001
   Neurology                         2.1                2.1                                2.9                            0.23
  Site investigator specialty                                                                                             
   Cardiology                        65                 66                                 58                             \<0.0001
   Electrophysiology                 15                 14                                 24                             
   Internal medicine/primary care    20                 20                                 18                             

Continuous variables are presented as median and interquartile range. AF indicates atrial fibrillation; EHRA, European Heart Rhythm Association.

Antithrombotic Therapy by CHADS~2~ Score and Previous AF Ablation
-----------------------------------------------------------------

Antithrombotic therapy according to CHADS~2~ score and previous AF ablation is summarized in [Table 3](#tbl3){ref-type="table"}. Three quarters of the patients in ORBIT-AF were on oral anticoagulation therapy at baseline, regardless of whether or not they had a history of catheter ablation of AF (75% vs. 76%; *P*=0.5). Dabigatran use was higher among patients with previous catheter ablation of AF (9.5% vs. 4.7%; *P*\<0.0001), whereas warfarin was more common in nonablated patients (66% vs. 72%; *P*=0.0036). However, ablated patients were more likely to have been treated with warfarin in the past. In addition, use of aspirin was more common in patients with previous AF ablation. Both previously ablated and nonablated patients were highly likely to be on some form of antithrombotic therapy (95% vs. 95%; *P*=0.8).

###### 

Antithrombotic Therapy by CHADS~2~ Score and Previous AF Ablation

                                                              No Previous AF Catheter Ablation   Previous AF Catheter Ablation   *P* Value (No Previous Ablation vs. Previous Ablation)                                                       
  ----------------------------------------------------------- ---------------------------------- ------------------------------- -------------------------------------------------------- ----- ---------- ----- ----- ----- ----- ---------- ----------
  Currently on antithrombotic therapy (other than warfarin)   50                                 54                              50                                                       50    0.18       59    61    61    57    0.7        0.0001
   Asprin                                                     43                                 48                              43                                                       43    0.07       50    54    52    47    0.4        0.0047
   Clopidogrel                                                7.2                                3.9                             44                                                       8.3   \<0.0001   6.3   2.3   6.0   7.6   0.19       0.4
   Prasugrel                                                  0.1                                0.2                             0.3                                                      0.1   0.3        0.2   0     0.7   0     0.3        0.8
   Ticagrelor                                                 0                                  0                               0                                                        0     --         0     0     0     0     --         --
   Aggrenox                                                   0.2                                0.2                             0.2                                                      0.2   0.9        0     0     0     0     --         0.4
   Other antithrombotic                                       0.6                                0.0                             0.5                                                      0.6   0.16       0     0     0     0     --         0.087
  Oral anticoagulation therapy                                                                                                                                                                                                                
   Treated with warfarin in the past                          81                                 61                              75                                                       84    \<0.0001   92    90    92    93    0.6        \<0.0001
   Warfarin                                                   72                                 46                              64                                                       76    \<0.0001   66    47    55    77    \<0.0001   0.0037
   Dabigatran                                                 4.7                                5.8                             6.6                                                      4.1   \<0.0001   9.5   9.2   8.7   10    0.9        \<0.0001
   Warfarin or dabigatran                                     76                                 51                              71                                                       80    \<0.0001   75    56    64    86    \<0.0001   0.5
   Contraindications to anticoagulation therapy               13                                                                                                                                           11                                 0.26
  Any antithrombotic therapy, including warfarin              95                                 87                              94                                                       96    \<0.0001   95    93    95    96    0.6        0.8

AF indicates atrial fibrillation.

Patients with a lower CHADS~2~ score were less likely to be on oral anticoagulation therapy than those with higher scores, regardless of previous AF ablation. This was particularly evident for warfarin treatment (patients with previous catheter ablation: 66% \[CHADS~2~=0, CHADS~2~=1, CHADS~2~≥2: 47%, 55%, 77%\], *P*\<0.0037; patients without previous catheter ablation: 72% \[CHADS~2~=0, CHADS~2~=1, CHADS~2~≥2: 46%, 64%, 76%\], *P*\<0.0001), whereas the findings for dabigatran were less clear. Over half of the patients with a CHADS~2~ score of 0 were on oral anticoagulation therapy in both groups. Of the patients with previous catheter ablation, 69 (13%) were within the 2-month period immediately postablation, when anticoagulation is recommended irrespective of CHADS~2~-score.[@b2] As expected, the rate of oral anticoagulation treatment (warfarin or dabigatran) was high overall (87%), as well as across the different CHADS~2~ score strata (CHADS~2~=0, CHADS~2~=1, CHADS~2~≥2: 79%, 83%, 94%, *P*=0.2842) in this group.

Factors Associated With Previous AF Catheter Ablation
-----------------------------------------------------

Factors independently associated with previous catheter ablation of AF are summarized in [Figure](#fig01){ref-type="fig"}. In addition to being treated by an electrophysiologist (adjusted OR, 3.00; 95% CI, 2.31 to 3.90; *P*\<0.0001), the factor with the strongest association with a higher likelihood of previous AF ablation was AF duration more than 12 months (adjusted OR, 2.85; 95% CI, 2.05 to 3.96; *P*\<0.0001). In contrast, the factors with the strongest association with a lower likelihood of previous AF ablation were increasing age (adjusted OR, 0.65; 95% CI, 0.58 to 0.72 per 5-year increase beyond 70 years; *P*\<0.0001), severely reduced LVEF (adjusted OR, 0.41; 95% CI, 0.23 to 0.74; *P*=0.0033) and being of nonwhite race ([Figure](#fig01){ref-type="fig"}).

![Forest plot of factors associated with a history of catheter ablation at baseline. AF indicates atrial fibrillation; CL, confidence level; Hx, history; LCL, lower confidence level; LVEF, left ventricular ejection fraction; OR, odds ratio; UCL, upper confidence level.](jah30004-e001901-f1){#fig01}

Previous AF Ablation and Associations With Outcome
--------------------------------------------------

Patients with a previous AF ablation had more repeat CV hospitalizations per 100 patient-years than without ablation in the unadjusted analysis (30.19 vs. 24.01; unadjusted RR, 1.26; 95% CI, 1.05 to 1.50; *P*=0.0126), but this difference was not statistically significant in the adjusted model (adjusted RR, 1.11; 95% CI, 0.93 to 1.33; *P*=0.2289). [Table 4](#tbl4){ref-type="table"} summarizes repeat hospitalizations during follow-up. During follow-up, risks of all-cause mortality (unadjusted HR, 0.50; 95% CI, 0.33 to 0.75; *P*=0.0008), CV death (unadjusted HR, 0.46; 95% CI, 0.24 to 0.89; *P*=0.0222) as well as the composite endpoint of death, stroke/TIA, and CHF (unadjusted HR, 0.54; 95% CI, 0.39 to 0.74; *P*=0.0001) were significantly lower in patients with a previous AF ablation, compared to patients without. However, no statistically significant differences were noted in any outcome in the adjusted models. [Table 5](#tbl5){ref-type="table"} summarizes the associations between outcome variables and previous AF ablation.

###### 

Repeat Hospitalizations in Full Follow-up (N=9488)

  Outcome     Previous AF Ablation   No Previous AF Ablation   Unadjusted RR (95% CI)   *P* Value   Adjusted RR (95% CI)   *P* Value
  ----------- ---------------------- ------------------------- ------------------------ ----------- ---------------------- -----------
  All-cause   446 (51.72)            7551 (52.76)              0.98 (0.85, 1.13)        0.7802      1.04 (0.91, 1.19)      0.5810
  CV          260 (30.19)            3458 (24.01)              1.26 (1.05, 1.50)        0.0126      1.11 (0.93, 1.33)      0.2289
  Bleeding    28 3.22)               592 (4.03)                0.80 (0.52, 1.23)        0.3110      1.10 (0.71, 1.72)      0.6722

AF indicates atrial fibrillation; CI, confidence interval; CV, cardiovascular; RR, relative risk.

###### 

Association of Previous Catheter Ablation and Outcomes in Follow-up (N=9451)

  Outcome                             Previous AF Ablation   No Previous AF Ablation   Unadjusted HR (95% CI)   *P* Value   Adjusted HR (95% CI)   *P* Value
  ----------------------------------- ---------------------- ------------------------- ------------------------ ----------- ---------------------- -----------
  All-cause death                     24 (2.73)              833 (5.55)                0.50 (0.33, 0.75)        0.0008      0.78 (0.52, 1.18)      0.2459
  CV death                            9 (1.03)               331 (2.22)                0.46 (0.24, 0.89)        0.0222      0.70 (0.36, 1.38)      0.3050
  First CV hospitalization            163 (23.03)            2270 (17.76)              1.17 (0.99, 1.38)        0.0628      1.06 (0.90, 1.26)      0.4795
  All-cause death/stroke/TIA or CHF   39 (4.51)              1229 (8.42)               0.54 (0.39, 0.74)        0.0001      0.78 (0.56, 1.09)      0.1417
  Major bleeding                      29 (3.39)              575 (3.95)                0.81 (0.55, 1.18)        0.2767      1.08 (0.74, 1.59)      0.6901

A complete list of the variables in the adjusted models can be found in [Data S1](#sd1){ref-type="supplementary-material"}. AF indicates atrial fibrillation; CHF, congestive heart failure; CI, confidence interval; CV, cardiovascular; HR, hazard ratio; TIA, transient ischemic attack.

Incident AF Ablation and Associations With Outcome
--------------------------------------------------

During follow-up, 266 patients underwent a catheter ablation of AF. These patients were compared to 515 matched controls. Compared to controls, patients with an incident AF ablation had a lower rate of all-cause (1.60 vs. 2.00 events per 100 patient-years) and CV death (0.32 vs. 1.11 events per 100 patient-years), but these differences did not reach statistical significance (adjusted HR, 0.75; 95% CI, 0.27 to 2.08; *P=*0.57; and HR, 0.32; 95% CI, 0.05 to 2.01; *P*=0.22). Patients with incident ablation were more frequently hospitalized because of CV causes (36.14 vs. 21.62 events per 100 patient-years; adjusted HR, 1.67; 95% CI, 1.24 to 2.26; *P*=0.0008) than matched patients without incident ablation, whereas the other outcomes included were similar ([Table 6](#tbl6){ref-type="table"}).

###### 

Association of Incident Catheter Ablation and Outcomes in Follow-up (N=781)

  Outcome                             Incident Catheter Ablation (N=266)   No Incident Catheter Ablation (N=515)   Adjusted HR (95% CI)   *P* Value
  ----------------------------------- ------------------------------------ --------------------------------------- ---------------------- -----------
  All-cause death                     5 (1.60)                             18 (2.00)                               0.75 (0.27, 2.08)      0.5774
  CV death                            1 (0.32)                             10 (1.11)                               0.32 (0.05, 2.01)      0.2246
  First CV hospitalization            85 (36.14)                           158 (21.62)                             1.67 (1.24, 2.26)      0.0008
  All-cause death/stroke/TIA or CHF   14 (4.59)                            41 (4.65)                               1.02 (0.53, 1.95)      0.9616
  Major bleeding                      7 (2.27)                             21 (2.39)                               1.07 (0.43, 2.68)      0.8843

A complete list of the variables in the adjusted models can be found in [Data S1](#sd1){ref-type="supplementary-material"}. CHF indicates congestive heart failure; CI, confidence interval; CV, cardiovascular; HR, hazard ratio; TIA, transient ischemic attack.

Discussion
==========

The major finding in our analysis is that catheter ablation is a relatively infrequent rhythm control intervention. Only a small minority (5%) of AF patients in this nation-wide community practice cohort were previously treated with catheter ablation. This is in line with the rather strict criteria for referring patients to catheter ablation according to current guidelines.[@b2] The proportion is very similar to the rates reported in the Euro Heart Survey, where the rate of ablation is 5% in paroxysmal AF and 4% in patients with persistent AF.[@b9] However, several studies illustrate that there are regional, as well as temporal, differences in utilization rates of AF ablation.[@b1],[@b10],[@b11] The rapidly growing number of patients being considered for AF ablation is well illustrated by the fact that, during follow-up in ORBIT-AF, the number of patients who had undergone a catheter ablation of AF increased by approximately 50%.

According to current guidelines, the main criteria for considering a patient with AF for ablation are symptoms, drug resistance, and type of AF (ie, primarily paroxysmal and persistent).[@b2] It is therefore reassuring to find that patients with a previous catheter ablation in ORBIT-AF were more symptomatic, had higher burden of previous antiarrhythmic drug therapy, and also more seldom had permanent or newly diagnosed AF. In addition, patients with previous ablation were younger and had less comorbidity. This indicates that current practice patterns are in line with professional society guidelines. Although patients with previous ablation were younger than their nonablated counterparts, their mean age was still substantially higher than the mean age of ablated patients in the randomized, clinical trials,[@b3],[@b4] similar to previously reported registry data.[@b7] Randomized, clinical trial data for AF ablation in the elderly are lacking,[@b12] and, consequently, the current guidelines state that more research is needed to establish the role of catheter ablation of AF in the elderly.[@b2] Data on the comorbidity of patients undergoing catheter ablation of AF in community practice are sparse, but the findings in the present study fit well with previously described community-based populations of rhythm-controlled AF patients.[@b5],[@b6] Patients undergoing AF ablation have fewer CV and non-CV comorbidities.

A more provocative finding is the lower proportion of minorities among patients with a previous catheter ablation of AF. This reflects similar findings involving other cardiac procedures as well as AF ablation[@b10],[@b13],[@b14]; however, the reasons for this disparity in the management of patients with AF are not clear. Another disparity was also observed with respect to patient educational status. In this cohort, a higher level of education was associated with a higher rate of catheter ablation of AF. Educational level has been shown to be associated with symptom severity in AF and also with "health literacy" in general (ie, the ability to seek, understand, and use health information).[@b15],[@b16] Further studies are needed to define the causes of these disparities and ultimately guide their correction.

Although the evidence base for catheter ablation is well established, there are few national reports from routine clinical practice. However, almost one third of the patients still had severe or disabling symptoms, despite ablation, and almost half of them had ongoing antiarrhythmic treatment. The continued symptom burden in patients with drug-refractory AF postablation illustrates the well-described shortcomings of AF ablation and the need for further improvement.[@b17] Fortunately, many procedural innovations are being investigated to improve the efficacy and safety of AF ablation, including contact-force sensing, alternative energy sources for ablation, and targeting of additional mechanisms of AF, including rotor ablation.[@b18]--[@b20]

Although preliminary registry data in relatively small cohorts without longer-term follow-up fail to identify significant stroke risk after discontinuation of oral anticoagulation therapy in patients after a successful ablation of AF,[@b21],[@b22] current guidelines caution against weighing rhythm status and previous catheter ablation of AF when assessing stroke risk.[@b2] Therefore, it is reassuring that only minor differences in oral anticoagulation use between patients with and without a previous catheter ablation of AF were observed. The rate of patients treated with any oral anticoagulation was similar in both groups, as was the rate of contraindication to oral anticoagulation. In summary, the findings in the current analysis indicate that physicians do not underestimate stroke risk nor do they withhold therapy in moderate-to high-risk patients after catheter ablation of AF.

Although the presence of sinus rhythm has been shown to be associated with a more favorable prognosis in AF,[@b23] and data from nonrandomized studies indicate that patients who have undergone pulmonary vein isolation experience improved outcomes,[@b24]--[@b26] reduction of stroke or mortality has not been demonstrated in a prospective, randomized, clinical trial. Several unadjusted differences in outcome between patients with a history of AF ablation and nonablated patients were noted in the present analysis (eg, a lower death rate and higher rates of hospitalization). However, after adjusting for relevant covariates, none of these associations remained. Similarly, the differences in outcome noted in patients with and without incident catheter ablation were entirely driven by differences in hospitalization rates, whereas rates of major adverse outcomes were similar. Importantly, a higher risk of hospitalization in patients on a rhythm-control strategy, when compared to patients on rate control, has been reported previously.[@b27] This is likely to reflect the fact that patients referred for AF ablation are more symptomatic and, although thoroughly matched, residual, unmeasured confounding factors may remain and, at least in part, explain this finding. It is important to highlight that there was limited statistical power to detect meaningful, clinically relevant differences in the major CV outcomes (eg, stroke, CV death, and all-cause mortality) owing to the low number of events. Despite the absence of statistical significance, several of the event rates were numerically lower in the ablation arm. Thus, it is possible that a beneficial association with catheter ablation may have been demonstrable in a larger population. Intuitively, the impact of AF ablation (if any) is likely to be different if the ablation is successful or not.[@b26] In that respect, the present analysis is hampered by the fact that there was no prespecified way of determining whether or not an ablation was considered successful (neither subjectively nor objectively). It is plausible that a successful AF ablation does have an impact on outcome, but the extent of that influence may be too small to detect when attenuated by the unsuccessful ablations.

The definite answer to whether or not catheter ablation of AF decreases death or stroke will require a prospective, randomized trial, as with the ongoing Catheter Ablation versus Anti-arrhythmic Drug Therapy for Atrial Fibrillation trial (CABANA) ([clinicaltrials.gov](http://clinicaltrials.gov)).

Limitations
-----------

These data are derived from a voluntary, observational study and thus are susceptible to the limitations inherent in such methods. These include both selection and reporting biases. Based on available data, there is no way to separate successful or unsuccessful ablations. Per protocol, ECGs were recorded every 6 months, and, consequently, more-detailed data on AF burden are not available. The data in this study are dependent on the quality of medical record documentation and abstraction. The utilization catheter ablation of AF was not randomized; therefore, despite multivariable adjustment, it is possible that residual, unmeasured confounding remains. Although the trends observed in ORBIT-AF are similar to those in other observational data, we cannot exclude that participation in ORBIT-AF may have highlighted symptoms that made rhythm control more likely. Finally, it is also possible that our analyses were limited by the sample size and reduced power to demonstrate a difference in outcomes.

Conclusion
==========

In U.S. clinical practice, a minority of patients is managed with ablation. However, a significant portion of ablation patients had moderate or severe symptoms and required antiarrhythmic therapy, even after ablation. Factors associated with catheter ablation were primarily factors highlighted in current guidelines; however, nonwhite patients and those with less education were less likely to be treated with catheter ablation. There were no clinically relevant differences in oral anticoagulation post-AF ablation or differences in outcomes in patients with or without previous AF catheter ablation, but patients with incident AF ablation are hospitalized more often during the remainder of the follow-up.
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[^1]: An accompanying [Data S1](#sd1){ref-type="supplementary-material"} is available at <http://jaha.ahajournals.org/content/4/5/e001901/suppl/DC1>
